Eplerenone

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1943 publications

Eplerenone Revisited: A Balanced Reappraisal of Its Role in Hypertension, Heart Failure, and Cardiorenal Disease.

Eplerenone Revisited: A Balanced Reappraisal of Its Role in Hypertension, Heart Failure, and Cardiorenal Disease.

Journal: Journal of cardiovascular pharmacology

Published: August 19, 2026

MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials.

MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials.

Journal: Circulation. Heart failure

Published: August 07, 2026

Evaluating the Efficacy and Safety of Topical Difluprednate in Patients with Chronic Central Serous Chorioretinopathy.

Evaluating the Efficacy and Safety of Topical Difluprednate in Patients with Chronic Central Serous Chorioretinopathy.

Journal: Retina (Philadelphia, Pa.)

Published: July 30, 2026

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure.

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure.

Journal: Journal of the American College of Cardiology

Published: July 13, 2026

Abnormal activation of the mineralocorticoid receptor in the aldosterone-sensitive distal nephron contributes to fructose-induced salt-sensitive hypertension.

Abnormal activation of the mineralocorticoid receptor in the aldosterone-sensitive distal nephron contributes to fructose-induced salt-sensitive hypertension.

Journal: American journal of physiology. Renal physiology

Published: July 11, 2026

Abnormal activation of the mineralocorticoid receptor in the aldosterone-sensitive distal nephron contributes to fructose-induced salt-sensitive hypertension.

Abnormal activation of the mineralocorticoid receptor in the aldosterone-sensitive distal nephron contributes to fructose-induced salt-sensitive hypertension.

Journal: American journal of physiology. Renal physiology

Published: July 11, 2026

Finerenone and Cardiorenal Outcomes: A Narrative Review.

Finerenone and Cardiorenal Outcomes: A Narrative Review.

Journal: Cardiology in review

Published: June 29, 2026

Cardiorenal Effects of Switching from Eplerenone to Esaxerenone in Patients with Chronic Heart Failure and Hypertension: A Prospective Clinical Study.

Cardiorenal Effects of Switching from Eplerenone to Esaxerenone in Patients with Chronic Heart Failure and Hypertension: A Prospective Clinical Study.

Journal: Journal of personalized medicine

Published: June 29, 2026

Baxdrostat (Baxfendy) - an aldosterone synthase inhibitor for hypertension.

Baxdrostat (Baxfendy) - an aldosterone synthase inhibitor for hypertension.

Journal: The Medical letter on drugs and therapeutics

Published: June 25, 2026

Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.

Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.

Journal: Journal of clinical medicine

Published: June 24, 2026

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Journal: Retina (Philadelphia, Pa.)

Published: June 22, 2026

Which aldosterone antagonist? Choosing between sprionolactone and the novel drug finerenone

Which aldosterone antagonist? Choosing between sprionolactone and the novel drug finerenone

Journal: Nederlands tijdschrift voor geneeskunde

Published: June 15, 2026

Showing 1-12 of 1,943

Last Updated: 09/26/2026